|
1
|
In-center hemodialysis six times per week versus three times per week.
|
N Engl J Med
|
2010
|
10.73
|
|
2
|
Effect of dialysis dose and membrane flux in maintenance hemodialysis.
|
N Engl J Med
|
2002
|
10.52
|
|
3
|
Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study.
|
J Am Soc Nephrol
|
2005
|
2.07
|
|
4
|
Effects of frequent hemodialysis on measures of CKD mineral and bone disorder.
|
J Am Soc Nephrol
|
2012
|
1.75
|
|
5
|
Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study.
|
J Am Soc Nephrol
|
2003
|
1.56
|
|
6
|
Unexplained nephrotic-range proteinuria in a 38-year-old man: a case of "no change disease".
|
Am J Kidney Dis
|
2004
|
1.54
|
|
7
|
Factors that affect postdialysis rebound in serum urea concentration, including the rate of dialysis: results from the HEMO Study.
|
J Am Soc Nephrol
|
2004
|
1.31
|
|
8
|
Association of achieved dialysis dose with mortality in the hemodialysis study: an example of "dose-targeting bias".
|
J Am Soc Nephrol
|
2005
|
1.16
|
|
9
|
Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
|
Am J Kidney Dis
|
2013
|
1.10
|
|
10
|
Baseline physical performance, health, and functioning of participants in the Frequent Hemodialysis Network (FHN) trial.
|
Am J Kidney Dis
|
2011
|
1.10
|
|
11
|
Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients.
|
Clin J Am Soc Nephrol
|
2007
|
1.07
|
|
12
|
Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis.
|
Hemodial Int
|
2012
|
0.98
|
|
13
|
Determinants of cardiac autonomic dysfunction in ESRD.
|
Clin J Am Soc Nephrol
|
2010
|
0.90
|
|
14
|
The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients.
|
Am J Nephrol
|
2003
|
0.89
|
|
15
|
Seasonal variations in clinical and laboratory variables among chronic hemodialysis patients.
|
J Am Soc Nephrol
|
2002
|
0.88
|
|
16
|
Safety and efficacy of regional citrate anticoagulation during 8-hour sustained low-efficiency dialysis.
|
Clin J Am Soc Nephrol
|
2008
|
0.86
|
|
17
|
Hand-assisted laparoscopic radical nephrectomy-associated rhabdomyolysis with ARF.
|
Am J Kidney Dis
|
2003
|
0.79
|
|
18
|
A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.
|
Am J Kidney Dis
|
2007
|
0.78
|
|
19
|
Hemodialysis: techniques and prescription.
|
Am J Kidney Dis
|
2005
|
0.77
|
|
20
|
Multiple complications in multiple myeloma.
|
Am J Kidney Dis
|
2005
|
0.77
|
|
21
|
Imatinib therapy for non-infection-related type II cryoglobulinemia with membranoproliferative glomerulonephritis.
|
Am J Kidney Dis
|
2011
|
0.77
|
|
22
|
Mortality and treatment modality of end-stage renal disease.
|
Ann Intern Med
|
2005
|
0.76
|
|
23
|
Novel dialysis modalities: do we need new metrics to optimize treatment?
|
J Clin Pharmacol
|
2012
|
0.75
|
|
24
|
In-center thrombolysis for clotted AV access: a cohort review.
|
Semin Dial
|
2012
|
0.75
|